Objective: Despite the existence of several therapeutic strategies, the management of cervical cancer remains challenging. Our region has very little data on the interaction between the immune system and the clinical response to chemotherapy. This work examines plasma levels of galectin-3 (Gal-3) and percentages of activated T cells in patients with cervical cancer treated with chemotherapy and investigates if there is a relationship between the rates of these two elements. Methods: We compared data from 37 patients with cervical cancer undergoing chemotherapy and 42 controls with normal cervical cytology. Plasma Gal-3 concentrations were assessed by ELISA and expression of activation markers by T cells (CD69 and HLA-DR) was assessed by flow cytometry at three different time points during chemotherapy. Results: Our results showed that patients had a significantly higher concentration of Gal-3 compared to controls (4.025 vs. 1.340, p 0.001), similarly, they had a significantly high percentage of activated lymphocytes (2.610 vs. 0.731; p 0.0001). According to the response to treatment, patients with no response to treatment had a lower concentration of circulating Gal-3 but had approximately the same percentage of activated CD4 and CD8 lymphocytes as patients with a partial or total response. In addition, we found a positive correlation between the Gal-3 level and CD4 T cells expressing the activation marker CD69 (p 0.05; rho = 0.44). Conclusion: In conclusion, our results show that there would be a relationship between circulating galectin-3 and the percentage of peripheral CD4+CD69+ cells in cervical cancer.

Background: In 2019, the WHO estimated that over 296 million people were living with chronic hepatitis B virus (HBV) infection and over 820,000 deaths attributable to hepatitis B. Most people living with HBV are unaware of their immune status and live in endemic areas. This is the case of Benin and Senegal, which have little data on the disease. Objective: This study aimed to provide epidemiological furthers on hepatitis B in Dakar and Cotonou according to WHO recommendations about “obtaining data for action”. Materials and Methods: Our study took place at the Medical Biology Laboratory of the Idrissa Pouye General Hospital (LBM-HOGIP) in Dakar, Senegal. Participants were selected at the LBM-HOGIP of Dakar or at the LBMs of the health centres of the Archdiocese of Cotonou respectively from November to December 2019 and February to March 2020. All participants were tested for hepatitis B virus antigen (HBsAg) using a microparticle chemiluminescence immunoassay assay. Other risk factors including blood transfusion, haemodialysis, tattooing, cultural or clan scarification, piercing, injecting drug use, unprotected sex and surgical procedures were also investigated. Informed consent was obtained from each participant. The study was approved by the ethics committees in Senegal and Benin. For the biological tests, Excel and IBM SPSS Statistics software were used for the analysis of the results. Results: A total of 470 participants were recruited including 234 in Cotonou and 236 in Dakar. The median age in Cotonou was 29 years with extremes of 10 and 65 years, and 38 years in Dakar with extremes of 6 and 93 years. The prevalence of HBsAg was 12.39% in Cotonou and 19.91% in Dakar. The most affected age groups were 20 - 29 in Dakar and 30 - 39 in Cotonou. Except for piercing, none of the other risk factors considered in our study were found to be associated with HBV transmission in our populations. Conclusion: Our study is hospital-based and revealed high prevalence of HBsAg. These prevalences were higher in men.

Background: Tuberculosis (TB) is one of the world’s deadliest infectious diseases. Tumor necrosis factor-Alpha (TNF-α) and Interleukin 8 (IL-8) are involved in the pathogenesis of pulmonary TB (PTB). However, the contribution of polymorphisms of these cytokines to PTB susceptibility needed more investigation across geographic regions and ethnic groups. Purpose: The aim of this study was to investigate the association of the TNF-α-308 G/A and IL-8-251T/A polymorphisms with PTB risk in the Congolese population. Methods: This case-control study included 150 PTB patients and 160 control subjects. Blood samples were collected from all participants and were used for the TNF-α-308 G/A and IL-8-251T/A genotyping by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Odds ratios (OR) were calculated to estimate the potential polymorphism associations. A P level of Results: A significant difference was found between PTB patients and controls regarding the TNF-α-308AA genotype (P = 0.035) distribution. Moreover, this genotype was associated with risk to TB (OR = 7.19, 95% CI = 0.85 - 60.65, P = 0.035). The A allele was significantly more frequent in PTB patients than in controls, and was associated with risk to PTB (OR = 1.68, 95% CI = 1.05 - 2.68, P = 0.014). Regarding the IL-8-251T/A gene, TA and AA genotypes were significantly more frequent in PTB patients compared to controls, and were associated with increased risk to PTB (OR = 2.64, 95% CI = 0.97 - 7.18, P = 0.031 and OR = 3.0, 95% CI = 1.13 - 7.98, P = 0.014, respectively). However, the IL-8-251 A allele was not associated to PTB susceptibility (OR = 0.27, 95% CI = 0.15 - 0.44). Conclusion: TNF-α-308G/A and IL-8-251T/A polymorphisms may be associated to PTB susceptibility in the Congolese population, and the AA genotype of both cytokines could be a risk factor.

Elderly individuals, especially those with pre-existing conditions like type 2 diabetes mellitus (T2DM), have a high risk for developing severe cases of COVID-19. The aim of this work was to characterize the alterations of blood immune cells (BIC) in patients with symptomatic COVID-19 and confirmed SARS-CoV-2 infection, ≥60 years and who needed hospitalization in the Centro de Salud Hospital of Tucuman, Argentina, during the second peak of the pandemic in Argentina. Ten patients were enrolled from December 2020 to May 2021. Blood samples were taken at the time of admission (day 0) and five days after (day 5) for routine laboratory tests and the characterization of BIC by flow cytometry. Most of the patients were men (70%) aged between 60 and 78 years. The 70% of patients had T2DM while 50% had arterial hypertension. At day 0, all the patients had increased neutrophils and inflammatory markers (C reactive protein and D-dimers) and reduced numbers of lymphocytes, HLA-DRhi monocytes, CD16+CD56+ NK cells, CD3+HLA−DR+CD25+ cells, CD4+ and CD8+ T cells in blood. Patients received a standard treatment for COVID-19 care (O2, corticosteroids and antibiotics). The hospital treatment normalized the levels of BIC (day 5) in 30% of patients who were those with no comorbidities. In patients with T2DM, BIC recovery was variable. In T2DM patients who required administration of plasma (30%), prolonged O2 therapy (40%) or referral to the intensive care unit (10%) significant reductions of CD16+CD56+, CD3+HLA−DR+CD25+, CD4+ and CD8+ cells were observed between days 0 and 5. In line with previous studies, our results show that absolute counts of major lymphocyte subsets in blood are significantly and substantially decreased during the course of severe COVID-19 disease in elderly patients. These BIC alterations may persist despite clinical care in elderly patients with T2DM. Further studies are needed to investigate the utility of early lymphocyte subset measurements as prognostic biomarkers of disease severity, mortality, and response to treatment in COVID-19 elderly patients with T2DM.

Toxoplasmosis is a cosmopolitan antrhropozoonosis widespread in mammals and birds. Normally asymptomatic in the subject health, it can have serious consequences for the fetus in the first trimester of pregnancy in the pregnant woman. It is in this context that we propose to assess the immune response to T. gondii in pregnant women in Bangui. This was a retrospective analytical study that consulted the records of pregnant women received in prenatal consultations at the Bangui Community Hospital Maternity ward from January 2019 to December 2019. Socio-demographic and laboratory data (IgM, IgG response to T. gondii) and results of HIV serology were collected from January to June 2021. Chi2 test was used. A total of 307 pregnant women were analyzed. The average age of the women included was 28 (±6) years. The average parity of the entire sample was 2.18 (±1.93). Toxoplasmosis infectious was 14.65%. Women with a positive IgM response accounted for 17.58% and those with an IgG-positive response for 42.99%. Patients with a positive HIV were 5.86%. Patients aged 20 - 29 had a serological profile suggesting a probable ongoing infection (p = 0.010). The paucipares were more represented with no statistically significant difference (p = 0.23). Pregnant women were not significantly exposed to toxoplasmosis infectious (p = 0.96). Immunized and non-immunized subjects were similarly exposed [OR = 0.97; CI 95% 0.4 = 6 - 2.05]. Toxoplasmosis remains particularly serious during pregnancy. Seroprevalence was significantly higher in the 20 - 24 year age group. Women were similarly exposed depending on whether they were immunized or not. This requires the establishment of a specific prevention program against this disease.